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recommendations were produced. The first recom-
mendation is a general statement indicating that bio-
logical therapy is not a first-line drug treatment option
and should only be used after conventional treatment
has failed. The second recommendation is also a ge -
neral statement about the broad concept of axSpA
adopted by these recommendations that includes both
non-radiographic and radiographic axSpA. Recom-
mendations 3 to 7 deal with the definition of active di -
sease (including the recommended threshold of 2.1 for
the Ankylosing Spondylitis Disease Activity Score [AS-
DAS] or the threshold of 4 [0-10 scale] for the Bath
Ankylosing Spondylitis Disease Activity Index [BAS-
DAI]), conventional treatment failure (nonsteroidal
anti-inflammatory drugs being the first-line drug treat-
ment), assessment of response to treatment (based 
on an ASDAS improvement  of at least 1.1 units or a 
BASDAI improvement of at least 2 units [0-10 scale] or
at least 50%), and strategy in the presence of an ina -
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AbstrAct
Objective: To update the recommendations for the
treatment of axial spondyloarthritis (axSpA) with bio-
logical therapies, endorsed by the Portuguese Society of
Rheumatology.
Methods: These treatment recommendations were for-
mulated by Portuguese rheumatologists based on lite -
rature evidence and consensus opinion. At a national
meeting, the recommendations included in this docu-
ment were discussed and updated. A draft of the full
text of the recommendations was then circulated and
suggestions were incorporated. A final version was
again circulated before publication and the level of
agreement among Portuguese Rheumatologists was
anonymously assessed using an online survey.
Results: A consensus was achieved regarding the ini-
tiation, assessment of response and switching of bio-
logical therapies in patients with axSpA. In total, se ven
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dequate response (where switching is recommended)
or in the presence of long-term remission (where a pro-
cess of biological therapy optimization can be consi -
dered, either a gradual increase in the interval between
doses or a decrease of each dose of the biological the -
rapy).
Conclusion: These recommendations may be used for
guidance in deciding which patients with axSpA
should be treated with biological therapies. They co -
ver a rapidly evolving area of therapeutic intervention.
As more evidence becomes available and more bio-
logical therapies are licensed, these recommendations
will have to be updated. 
Keywords: Portugal; axial spondyloarthritis; ankylo -
sing spondylitis; biological therapies; guidelines; re -
commendations.
introduction
In 2005, the first version of the recommendations of
the Portuguese Society of Rheumatology (SPR – So-
ciedade Portuguesa de Reumatologia) for the treatment of
ankylosing spondylitis (AS) with biological therapies
was published in Acta Reumatológica Portuguesa (ARP)1.
These recommendations were updated in 20112. Since
then new evidence has been published, the concept of
axial spondyloarthritis (axSpA), as comprising the en-
tire spectrum of patients with radiographic sacroiliitis
(AS) and without radiographic sacroiliitis (non-radio-
graphic axSpA), has become established, clinical trials
with patients covering the entire spectrum of axSpA
have been published, and a new class of biological di -
sease modifying anti rheumatic drugs (bDMARDs) has
emerged to treat patients with axSpA (IL17-blockers).
It was therefore felt timely to update the recommen-
dations for the use of biological therapies in patients
with axSpA.
There are currently five registered TNF-blockers for
the indication of axSpA: adalimumab, certolizumab,
etanercept, golimumab and infliximab (in alphabetical
order). These therapies can be used in monotherapy,
without the need to combine them with conventional
synthetic DMARDS (csDMARDs). All, except infli -
ximab, have European Medicines Agency (EMA) ap-
proval for both radiographic and non-radiographic
axSpA. Biosimilars of infliximab, etanercept and adali -
mumab are also approved by the EMA.3 IL17-blo cker
therapy (secukinumab) has only been approved by the
EMA for axSpA with radiographic sacroiliitis.4,5
This article presents the 2016 update of the Por-
tuguese recommendations for the use of biological
therapies in patients with axSpA. Although these na-
tional recommendations contain some original con-
cepts, their general structure follows the pattern of 
other international recommendations.6 They were for-
mulated by Portuguese rheumatologists based on li -
terature evidence and consensus opinion. At a natio -
nal meeting, the 7 recommendations included in this
document were discussed and updated. A draft of the
full text of the recommendations was then circulated
and suggestions were incorporated. A final version was
again circulated before publication and the level of
agreement among Portuguese Rheumatologists was
anonymously assessed using an online survey. Agree-
ment was measured on a 11-point numerical rating
scale (with the anchors 0 = “do not agree at all” and 
10 = “fully agree”). 
These recommendations may be used for guidance
on which patients with axSpA should be treated with
biological therapies and how to decide regarding con-
tinuation of treatment. 
1. criteriA for stArting biologicAl 
therApies And Assessing response to
treAtment
1.1. General statement
Recommendation 1: In axSpA, biological therapy
is recommended for patients with active disease
despite optimal conventional treatment
(treatment failure).
1.2. Classification of axSpA
Recommendation 2: Patients are classified as
having axSpA if they fulfill the Assessment of
Spondyloarthritis international Society (ASAS)
criteria for axSpA (or the modified New York
criteria for AS).
The main aim of this recommendation is to re-em-
phasise and again acknowledge the fact that radio-
graphic sacroiliitis is often a late finding in the axSpA
disease course, that magnetic resonance imaging (MRI)
may show evidence of inflammation before structural
damage becomes evident on plain radiographs, and
that patients with normal imaging results can still be
diagnosed as having axSpA based on a typical combi-
nation of clinical and laboratory features. Importan tly,
it has been shown that patients with non-radiogra phic
axSpA have similar disease burden as patients ful filling
the modified New York (mNY) criteria for AS7,8 and,
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overall, studies with TNF-blockers in patients with
non-radiographic axSpA have shown at least similar ef-
ficacy compared to studies performed in patients ful-
filling mNY criteria.9-21
Of note, non-radiographic axSpA is not necessarily
a pre-radiographic form of the disease, since many pa-
tients do not progress to AS.  The percentage of patients
who shift from non-radiographic axSpA to radio-
graphic axSpA is not easy to determine, mainly due to
methodological difficulties, particularly the variability
in reading and rating radiographic changes of the
sacroiliac joints. The transition rate from non-radio-
graphic axSpA to radiographic axSpA during the early
years of the disease seems to happen at a relatively low
pace (5–12% during 2 years of follow-up)22-24. Among
the possible factors associated with this shift, inflam-
mation (elevated serum C-reactive protein [CRP] le vels
or MRI inflammation of the sacroiliac joints), HLA-B27
positivity and smoking have been identified. We will
need to wait for studies with longer follow-up in order
to clarify whether these low rates of change remain sta-
ble over time, and also to confirm whether the above
characteristics are robust prognostic factors of the pro-
gression of structural damage of the sacroiliac joints24. 
This recommendation intentionally uses the word
“classify” and not the word “diagnose”, and it does not
dispute the fact that classification criteria differ from
diagnostic criteria. There are no diagnostic criteria for
axSpA and the diagnosis should always be a decision
taken by the rheumatologist based on clinical, labora-
tory and imaging features, after having considered all
the potential differential diagnoses. In this context, the
aim of this recommendation is merely to highlight the
importance of repeating this diagnostic exercise when
the patient is considered for biological treatment, and
given that the ASAS criteria for axSpA have a good
balan ce between sensitivity and specificity (sensitivity
of 82.9% and specificity of 84.4%, in the original
study25,26; sensitivity of 82% and specificity of 88%, in
a more recent meta-analysis27) and excellent positive
predictive value (93.3% in the ASAS follow-up study)28
it was felt that verifying the fulfilment of the ASAS cri-
teria for axSpA (for classification purposes and after a
diagnosis has already been made) was a relevant exer-
cise to be made when re-evaluating a patient prior to
starting biological treatment. 
1.3. Definition of active disease
Recommendation 3: Active axial disease
candidate to biological therapy is defined by an
Ankylosing Spon dylitis Disease Activity Score
(ASDAS) ≥2.1 or a Bath Ankylosing Spondylitis
Activity Index (BASDAI) ≥4, on two separate
occasions, with at least 1 month inter val. The
decision to treat with bio logical therapy should
be supported by the rheumatologist’s opinion.
Historically, the BASDAI29 has been the most widely used
clinical disease activity measure in axSpA, and the BAS-
DAI cut-off ≥4 the most common selection criteria for
clinical trials with biological therapies. The ASDAS26,30-32
is a composite disease activity index more recently de-
veloped for axSpA, with validated disease activity cut-
-offs (an ASDAS ≥2.1 represents high disease activity).
An increasing number of clinical trials is now using AS-
DAS measures as primary or secondary endpoints.
The inclusion of the ASDAS as an alternative (and
preferred measure) to the BASDAI to define active 
axSpA disease is based on the good psychometric pro -
perties of this index32 and its validation among the
Outco me Measures in Rheumatology (OMERACT)
community33. There is also evidence that the ASDAS
may better reflect the inflammatory disease processes
in patients with axSpA34 and that ASDAS high disease
activity (ASDAS ≥2.1) may be a better cut-off than BAS-
DAI ≥4 to select patients for treatment with TNF-blo -
ckers35-37, namely because it selects a higher number of
patients with characteristics predictive of good res -
ponse to these therapies37.
It has also been shown that higher ASDAS levels may
contribute to syndesmophyte formation, while this has
not been shown for BASDAI alone (only for BASDAI in
combination with CRP)38,39. Furthermore, while a high
ASDAS was shown to be a predictor for continuation
of TNF-blockers, a high BASDAI appeared to be a pre-
dictor for stopping TNF-blockers. It should also be
highlighted that the ASDAS cut-offs for disease activi-
ty states and response criteria were based on a robust
validation process, while the BASDAI cut-offs were ar-
bitrarily chosen31.
Importantly, the decision to consider the disease as
active should be supported by the rheumatologist’s
opinion, who should base his judgment on clinical,
laboratorial (eg. CRP) and imaging (eg. MRI) features
of the disease. Of note, increased CRP levels and in-
flammation on MRI have been shown to be predictors
of a good response to TNF-blockers10,12,14,35,40,41 and,
whenever possible, the decision to treat with biologi-
cal therapies should take these factors into account.
It should be noted that the EMA approval for the
treatment of patients with radiographic axSpA (AS)
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with TNF-blockers is not dependent on any other pa-
tients’ characteristics (ie. fulfilment of mNY criteria for
AS suffices), while in patients with non-radiographic
axSpA this approval only applies to patients with an
ele vated CRP and/or inflammation on MRI. However,
given that MRI is still not widely available in a timely
fashion across all Portuguese Centres, and given the
limited availability of radiologists with an interest in
musculoskeletal diseases, rheumatologists opted not to
restrict the use of biologics in patients with non-radio-
graphic axSpA. Furthermore, data about the efficacy of
the IL17-blocker secukinumab and of the TNF-blo cker
infliximab in patients with non-radiographic axSpA are
still lacking and therefore these drugs lack EMA 
approval for non-radiographic axSpA. 
Finally, the group of rheumatologists decided that
none of the drugs should be prioritised over the other,
since efficacy with regard to musculoskeletal manifes-
tations seems comparable (although no solid head-to-
head comparisons are available)9-14,42. However, it was
acknowledged that given the more extensive expe -
rience (in particular to what concerns long-term safe-
ty) with TNF-blockers these are more likely to be pres -
cribed as first biologic compared to IL17-blockers.
Moreover, patients’ preferences/lifestyle and patients’
clinical characteristics should be taken into account
when prescribing a biologic drug, namely in the pre -
sence of certain extra-articular features: monoclonal
antibodies (adalimumab, infliximab and certolizumab;
no data on golimumab) are efficacious in preventing
the recurrence of uveitis and in the treatment of in-
flammatory bowel disease (IBD), whereas etanercept
has shown contradictory results for uveitis, less effica-
cy in psoriasis (no head-to-head comparisons though),
and is not efficacious in IBD43-52. On the other hand,
etanercept seems to have a lower tuberculosis risk com-
pared to monoclonal antibody TNF-blockers53. Secu -
kinumab should be avoided in patients with active IBD,
as secukinumab in comparison to placebo was not effi -
cacious in Crohn’s disease and resulted in more adverse
events.54
1.4. Definition of conventional treatment failure:
Recommendation 4: Conventional treatment
failure is defined as active disease despite a
continuous therapeutic trial with at least two
NSAIDs over at least a 2-week period each, at
maximum recommended anti-inflammatory doses,
unless contraindicated or if the patient develops
intolerance or side-effects. For axial disease, no
additional treatment with csDMARDs is required
before the initia tion of biological therapy. 
Patients with peripheral arthritis should have an
adequate trial (at least three months of full dose
treatment) with a csDMARD (preferably
sulfasala zine), unless contraindicated or if the
patient deve lops intolerance or side-effects. 
In the case of mo noarthritis or oligoarthritis 
(≤4 active joints) at least 1 intra-articular
injection with corticosteroids should also 
have been tried, as long as there is no 
contrain dication.
For symptomatic enthesitis, at least one local
steroid injection is required, as long as there is
no contraindication.
NSAIDs (classical or COX-2 inhibitors) have demons -
trated clinical efficacy in axial disease55-60, contrary to
csDMARDs, for which there is no evidence of clinical
efficacy61-63. 
All patients should have an adequate therapeutic 
trial of at least two NSAIDs over at least a 2-week peri-
od each, corresponding to a total of at least 4 weeks of
full-dose continuous NSAID treatment, unless con-
traindicated or if the patient develops intolerance or
side-effects. The literature about the length of time be-
yond which it would be unlikely that a NSAID would
be effective is scarce. Only a few trials provided detailed
information on the time course of efficacy and these
trials suggest that the maximum effect is achieved after
2 weeks.56,57 However, the evidence for recommending
this treatment period is limited and there are patients
that may still respond after 2 weeks of treatment. There-
fore, on a shared decision with the patient, the rheuma-
tologist may choose to reasonably expand this treat-
ment period for each NSAID.
There are studies suggesting some efficacy of sul-
fasalazine in peripheral disease and to a lesser degree
in the prevention of anterior uveitis.61-63 Regarding
methotrexate and leflunomide, data are very limited
and there is no evidence of efficacy in peripheral disea -
se64,65. Although it was recognized that methotrexate in
often prescribed in axSpA patients with peripheral
arthritis, no evidence based recommendation can
presently support this treatment. Therefore, slight
prefe rence was still given to sulfasalazine for axSpA pa-
tients with concomitant peripheral disease, despite
limi ted evidence. This preference is reflected in the
wording of the recommendation 4. 
It should be noted that when we speak about pe-
ripheral involvement in the context of the current
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recom mendations, it is assumed that the patients have
both axial and peripheral involvement, and that the pe-
ripheral disease is contributing to the overall level of
disease activity. Currently, biological therapies are not
licensed for patients with pure peripheral involvement
(peripheral SpA), unless they have been diagnosed with
psoriatic arthritis, for which SPR has recently pu -
blished specific recommendations66.  
1.5. Assessment of response to treatment
Recommendation 5: Response to treatment
should be assessed after at least 3 months of
continuous treatment with a biological therapy.
Response criteria are: 1) a decrease in ASDAS
≥1.1 units or 2) a decrease in BASDAI ≥50% or
≥2 units (0-10 scale).
The choice of at least a 3-month interval as the time for
evaluation of response to a biological agent was based
on observations from phase III trials with biologics,
where response rates generally stabilized from 3
months onwards67. The inclusion of the ASDAS res -
ponse as an alternative (and preferred measure) to the
BASDAI response in assessing efficacy of the biological
therapy was based on the improved psychometric pro -
perties of the ASDAS compared to the BASDAI26,30-32,35,68
and its validation among the OMERACT community33.
Furthermore, the ASDAS may better reflect the in-
flammatory disease processes in patients with axSpA
than the BASDAI34. Beyond that, post-hoc analyses of
the ASCEND trial demonstrated that ASDAS response
has better discriminatory capacity than BASDAI and
ASAS response69. In other studies, using data from 
other TNF-blocker trials, ASDAS showed better corre-
lation with improvement in MRI scores than BAS-
DAI70,71. Thus, and consistent with recommendation 2,
preference is given to ASDAS for assessing response to
treatment, while BASDAI is a possible alternative.
2. procedure in cAse of inAdequAte 
response to A biologicAl Agent
Recommendation 6: After 3-6 months of an
adequate dose of continuous treatment with a
biolo gic, we recommend switching the biological
therapy in non-respondent patients.
Patients have been switched successfully from one
TNF-blocker to another. There are several studies con-
firming a significant response to a second or third TNF-
-blocker72-78. A reduced response is seen more fre-
quently in patients who switched because of inefficacy
when compared with patients who switched due to ad-
verse events74. Furthermore, patients with secondary
loss of response seem to have a higher potential for res -
ponse to a second TNF-blocker switch than patients
who are primary non-responders79,80. There is no evi-
dence that a dose increase or a decrease in dose inter-
val enhances response. Secukinumab has shown effi-
cacy both in TNF-blocker-naive and TNF-blocker-ex-
perienced subjects with active AS, though a better
respon se was seen for the former5. No specific recom-
mendation was made regarding the prescription order
of biologic drugs when switching.
3. procedure in cAse of sustAined long-term
remission under A biologicAl Agent
Recommendation 7: In case of sustained inactive
disease (ASDAS<1.3) for more than 12 months
under biological therapy, a process of biological
the rapy optimization can be initiated (gradual
increase in the interval between doses or decrease
of each dose) on an individual basis and according
to the judgement of the rheumatologist.
Taking into account the potentially serious adverse ef-
fects and costs associated with biological therapies, it
seems reasonable to consider tapering these drugs in
axSpA patients in a sustained, inactive/remission state.
The same procedure is recommended for other drugs
with important side effects in rheumato logy, such as
NSAIDs or csDMARDs, as well as for bio logical thera-
pies in patients with rheumatoid arthritis81. One ran-
domized controlled trial has shown that reduced do ses
of TNF-blockers can be as effective as the standard dose
in a large proportion of AS patients (up to 52% of re-
sponders as defined by the BASDAI)82. Several obser-
vational studies have shown similar results in the cli -
nical setting, using pre-defined dose reduction sche -
dules or tailored approaches to reduce dose on an in-
dividual basis, with equivalent control of disease
activity, in even larger proportions of patients83-92. Re-
duced doses were also shown to be effective on spinal
inflammation on MRI93.
This approach should be thoroughly discussed with
the patient and supported by the rheumatologist opi -
nion. In such cases, a short-term reassessment of the
need of treatment readjustments should be planed. It
should be noted that although dose optimization seems
possible for many patients, most patients flare after full
discontinuation of treatment and only exceptionally re-
mission is maintained after discontinuation94. Never-
theless, the reintroduction of treatment seems safe and
effective95,96.
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conclusion
An updated consensus was achieved regarding the ini-
tiation, assessment of response and switching biologi-
cal therapies in patients with axSpA (Table 1). These
recommendations may be used for guidance in deci -
ding which patients with axSpA should be treated with
biological therapies. The benefit/risk profile of the pa-
tient should always be taken into account when pres -
cribing a biologic drug and the decision to treat with a
biological drug should be a process shared between the
patient and the physician. The description of contra-in-
dications to biological treatment are outside the scope
of this article and there are already position papers or
tAble i. recommendAtions for the use of biologicAl therApies in pAtients with AxiAl
spondyloArthritis 
Agreement 
mean (SD) 
Domain Recommendation % scores ≥8
General In axSpA, biological therapy is recommended for patients with active disease 9.6 (0.8) 
recommendation despite optimal conventional treatment (treatment failure). 97.4%
Classification Patients are classified as having axSpA if they fulfill the ASAS criteria for axSpA 9.5 (0.8) 
of patients (or the modified New York criteria for AS). 97.4%
Active disease Active axial disease candidate to biological therapy is defined by an ASDAS ≥2.1 9.4 (1.0) 
or a BASDAI ≥4, on two separate occasions with at least 1 month interval. 97.4%
The decision to treat with biological therapy should be supported by the 
rheumatologist’s opinion.
Conventional Conventional treatment failure is defined as active disease despite a continuous 9.0 (1.5) 
treatment failure therapeutic trial with at least two NSAIDs over at least a 2-week period each 87.2%
at maximum recommended anti-inflammatory doses, unless contraindicated or 
if the patient develops intolerance or side-effects. For axial disease, no additional 
treatment with conventional synthetic DMARDs is required before the initiation 
of biological therapy. 
Patients with peripheral arthritis should have an adequate trial (at least three 
months of full dose treatment) with a conventional synthetic DMARD 
(preferably sulfasalazine), unless contraindicated or if the patient develops 
intolerance or side-effects. In the case of monoarthritis or oligoarthritis  
(≤ 4 active joints) at least 1 intra-articular injection with corticosteroids should 
also have been tried, as long as there is no contraindication.
For symptomatic enthesitis, at least one local steroid injection is required, as 
long as there is no contraindication.
Assessment of Response to treatment should be assessed after at least 3 months of continuous 9.3 (0.9) 
response treatment with a biological therapy. Response criteria are: 1) a decrease in 94.7%
BASDAI ≥50% or ≥2 units (0-10 scale) or 2) a decrease in ASDAS ≥1.1 units.
Inadequate After 3-6 months of an adequate dose of continuous treatment with a biologic, 9.3 (1.2) 
response we recommend switching the biological therapy in non-respondent patients. 89.5%
Long-term In case of sustained inactive disease (ASDAS<1.3) for more than 12 months 9.4 (0.9) 
“remission” under biological therapy, a process of biological therapy optimization can be 97.4%
initiated (gradual increase in the interval between doses or decrease of each dose) 
on an individual basis and according to the judgement of the rheumatologist.
Agreement was voted on a scale from 0 to 10 (fully disagree to fully agree) by 39 voting rheumatologists. 
AS – Ankylosing Spondylitis; ASAS – Assessment of Spondyloarthritis international Society; ASDAS – Ankylosing Spondylitis Disease
Activity Score; axSpA – axial spondyloarthritis; BASDAI – Bath Ankylosing Spondylitis Disease Activity Index; csDMARD – conventional
synthetic disease modifying anti-rheumatic drug; NSAIDs – nonsteroidal anti-inflammatory drugs; SD, standard deviation.
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recommendations issued by SPR regarding the use of
biosimilars, vaccination strategy and tuberculosis
screening in patients with immune mediated inflam-
matory diseases, including patients that are candidates
for treatment or already treated with biological thera-
pies3,97,98. The use of biological therapies in axSpA is a
rapidly evolving field. As more evidence becomes
availa ble and more biological therapies are licensed,
these recommendations will have to be updated. 
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